NuPathe clears new path to US approval of migraine patch with job and cost cuts
This article was originally published in Scrip
Executive Summary
With potential US FDA approval for its first marketed drug on the horizon, NuPathe has disclosed a cost-cutting strategy in documents filed with the US Securities and Exchange Commission (SEC) that includes a 50% workforce reduction and decreased expenditures related to commercialisation of the company's transdermal sumatriptan migraine patch product NP101.
You may also be interested in...
Finance Watch: Biopharma VC Explosion Extends To Tools, Services
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche’s COVID-19 Collaboration Strategy Sees Promise In Combinations
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
Amgen Hands Omecamtiv Back To Cytokinetics
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Need a specific report? 1000+ reports available
Buy Reports